Alkem Laboratories Limited (ALKEM) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Alkem Laboratories enters its Q1 FY27 results following a year of leadership transition and strategic expansion into the medical devices sector. Investors are looking for clarity on how the company's domestic branded-generics growth is tracking against a robust Indian Pharmaceutical Market, alongside the margin impact of raw material cost headwinds and the recent USFDA classification of its Daman facility.
| Results date | August 14, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 36,033 Mn |
| Previous quarter PAT | Rs. 2,365 Mn |
| Previous quarter EBITDA margin | 14.4% |
| Net debt (latest quarter) | Rs. 54.74 Bn |
| Market cap | Rs. 65,156.95 Cr |
| CMP | Rs. 5,449.5 |
Alkem Laboratories Limited Q1 Results Date and Time
The Board Meeting is scheduled for August 14, 2026, to approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
A conference call is scheduled for August 14, 2026, at 4:30 PM IST, hosted by Motilal Oswal Securities, with MD Sandeep Singh and CFO Nitin Agrawal representing the company.
What to expect from Alkem Laboratories Limited's Q1 FY27 results
Domestic branded-generics revenue is expected to outpace the broader Indian Pharmaceutical Market, which grew at 10.3–12% through April and May 2026, supported by Alkem's chronic therapy mix reaching 22% of branded generics. While the weakening rupee provides a tailwind to INR-reported US revenue, the Daman facility's OAI classification and ongoing base-pricing erosion of 3–4% may temper growth compared to the 26% YoY increase seen in Q4 FY26.
EBITDA margins are expected to be pressured relative to the 21.9% reported in Q1 FY26 due to the impact of Minimum Import Price (MIP) costs on PenG and higher R&D spending, though management aims to maintain the 20–21% band for the full year. Investors should monitor the normalization of the effective tax rate, which stood at 15.4% in the year-ago quarter, as a potential headwind to bottom-line growth.
Key Things To Watch
Performance vs Guidance Tracking: Management's progress against key annual targets for FY27.
- Domestic growth: Target 100-150 bps above IPM — Q1 IPM growth was 10-12%.
- EBITDA margin: Target 20-21% range — Q1 FY26 was 21.9%.
- R&D spend: Target 4.5-5% of revenue — FY26 actual was 4.2%.
- Capex: Target ~Rs. 750 Cr for FY27 — FY26 actual was Rs. 617 Cr.
Strategic Initiatives and Capex: Updates on recent acquisitions and CDMO operations.
- Occlutech integration: First full quarter of consolidation following July 2026 completion.
- Enzene US CDMO: Progress toward annual run rate of Rs. 300 Cr by March 2027.
- Semaglutide: India market share ramp-up for single-shot pre-filled syringes.
Risks and Headwinds to Monitor: Management-flagged operational and regulatory challenges.
- USFDA Daman OAI: Potential supply constraints or product registration delays for US market.
- MIP Cost Impact: Estimated annual impact of Rs. 80-100 Cr on PenG and derivatives.
- CEO Transition: Succession status following Dr. Vikas Gupta's resignation on June 30, 2026.
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
What is the status of the Daman manufacturing facility following the recent USFDA inspection?
The USFDA classified the Daman (Amaliya) facility as Official Action Indicated (OAI) on August 6, 2026, following a 7-observation Form 483. The company stated that manufacturing for the US market will continue while it works toward full compliance.
How did the company's domestic business perform relative to the market in FY26?
Alkem achieved an overall domestic outperformance of 20 bps over the Indian Pharmaceutical Market (IPM) in FY26. While the acute segment outperformed by 170 bps, the chronic segment saw a 10 bps outperformance.
What is the current status of the Occlutech acquisition?
Alkem Medtech completed the acquisition of a 51-55% stake in the Swiss company Occlutech Holding AG on July 17, 2026. The acquisition was funded by a Rs. 1,100 Cr rights issue in Alkem Medtech.
Related
- Alkem Laboratories Q1 FY27 Results Analysis: PAT Plunges 21.7%, Margin Compresses 140 bpsQ1 FY2026-2027 Results Analysis
- Alkem Laboratories Q1 FY27 Earnings Call: Raises India Guidance to 12%, Targets CDMO Breakeven in 4-5 QuartersQ1 FY2026-2027 Earnings Call
- ALKEM Q4 Results FY26 Preview: Date, Time, Expectations & Key Things To WatchQ4 FY2025-2026 Preview